This content is intended for healthcare professionals outside the UK and USA only.

Please confirm that you are a healthcare professional outside the UK and USA.


This activity has been funded by Amgen Inc. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Leukaemia, Immunotherapy, Paediatric Oncology View Time: 28 mins

touchEXPERT BRIEFING Front-line consolidation therapy in B-ALL: current challenges and novel strategies

Watch adult and paediatric oncologists discuss unmet needs in front-line B-ALL consolidation and in-development novel strategies.

Now Playing:
Up Next:
Expert Interviews
Treatment goals and challenges in front-line consolidation B-ALL therapy

In this video, Prof. Ribera and Prof. Rizzari discuss the goals and options for front-line consolidation in adults and paediatrics, in addition to current unmet needs.

view bio and disclosures
1/2 Next Interview
Leave Feedback

In this interview, Prof. Ribera and Prof. Rizzari answer the following questions:

  • What are the treatment goals for B-ALL in adults and paediatrics?
  • What are the current guideline recommendations for achieving these goals in terms of front-line consolidation treatment in B-ALL by MRD status in adults and paediatrics?
  • Given the multiple treatment options available for consolidation, how do you decide on treatment sequencing in MRD+ and MRD- patients, respectively in the post-induction setting in adults and paediatrics?
  • Where is there currently consensus in front-line consolidation treatments for Ph+ and Ph- disease in adults and paediatrics?
  • What are the current challenges and unmet needs in front-line consolidation treatments for Ph+ and Ph- disease in adults and paediatrics?
Novel front-line consolidation strategies for B-ALL

In this video, Prof. Ribera and Prof. Rizzari discuss novel front-line consolidation strategies in-development including their potential impact on adult and paediatric patients with B-ALL.

view bio and disclosures
2/2 Leave Feedback
Leave Feedback

In this interview, Prof. Ribera and Prof. Rizzari answer the following questions:

  • What novel immunotherapy-based consolidation strategies are under development in B-ALL for adults and paediatrics?
  • What treatment outcomes have been demonstrated so far with these strategies for adults and paediatrics?
  • What impact could these therapies have on the treatment paradigm for B-ALL in adults and paediatrics?
Leave Feedback
Overview & Learning Objectives

A range of consolidation treatment options for patients with Philadelphia chromosome (Ph) positive or negative status B-cell acute lymphoblastic leukaemia (B-ALL) are now available in both the adult and paediatric settings.1–3 However, disease outcomes remain suboptimal in some patients including post-consolidation relapses in adults with minimal residual negative disease and poor survival in certain paediatric subgroups, in addition to a need to reduce chemotherapy toxicity.4–7 In this activity, adult and paediatric oncologists discuss current challenges for front-line consolidation treatment in B-ALL and potential novel consolidation treatment strategies underdevelopment.

Learning Objectives

After watching this activity, participants should be better able to:

  • Describe the current recommendations for front-line consolidation treatment based on MRD status in adult and paediatric patients with B-ALL, including potential treatment sequencing
  • Discuss current challenges and consensus in frontline B-ALL treatment for Ph+ and Ph- disease
  • Outline potential novel front-line consolidation treatment strategies under development for adult and paediatric patients with B-ALL
Faculty & Disclosures
Prof. Carmelo Rizzari

University of Milano-Bicocca, IRCCS San Gerardo dei Tintori, Monza, Italy

Carmelo Rizzari is Professor of Paediatrics and head of the Paediatric Oncology Unit at the University of Milano-Bicocca, Italy, and President of SIOP Europe (the European Society for Paediatric Oncology).

He is a member of the AIEOP National Board (Italian Association for Paediatric Haematology and Oncology), Chairman of the AIEOP Clinical Pharmacology Committee, and a member of the AEIOP committee for first line and relapsed trials for acute lymphoblastic leukaemia. He has also served as the Principal or co-Principal Investigator for numerous academic or industry-sponsored clinical trials of innovative drugs for resistant/relapsed leukaemias and lymphomas, is author of a large number of scientific publications, and is actively involved in international scientific meetings and disease-specific working groups.

Prof. Rizzari discloses: Consultancy fees from Amgen, Clingen, Jazz Pharmaceuticals, and Servier. Grant and research support from Amgen, Clinigen, Jazz Pharmaceuticals, SERB and Servier. Honorarium from Amgen, Clinigen, Jazz Pharmaceuticals and Servier. Speaker’s bureau participant with Amgen, Clinigen, Jazz Pharmaceuticals and Servier.

Prof. Josep-Maria Ribera

Catalan Institute of Oncology, Josep Carreras Research Institute, Barcelona, Spain

Josep-Maria Ribera is Associate Professor of Medicine at the Autonomous University of Barcelona (UAB), Director of the Stem Cell Transplantation Unit at the Hospital Universitari Germans Trias i Pujol (HUGTP) and Head of the Clinical Hematology Department for the Catalan Institute of Oncology (ICO) also at HUGTP.

He is a member of the Steering Committee for acute lymphoblastic leukemia of the European LeukemiaNet and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL), in addition to teaching post-graduate courses at several higher education institutions in Span. His research focuses on the study of new treatment approaches and prognostic factors in adult ALL and he collaborates. He has authored/co-authored a large number of published clinical papers and book chapters on Haematology, Oncology and Internal Medicine.

Prof. Ribera discloses: Speaker and advisory boards honoraria from Amgen, Ariad, Pfizer and Shire. Clinical trials for Amgen, Ariad and Pfizer. Research support from Amgen.

  1. Network NCC. Acute Lymphoblastic Leukemia. Version 3.2023. Available at: (accessed November 2023). 2023.
  2. Hoelzer D, Bassan R, Boissel N, et al. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Ann Oncol 2023.
  3. Brown P, Inaba H, Annesley C, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18:81-112.
  4. Bassan R, Brüggemann M, Radcliffe HS, et al. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica 2019; 104:2028-39.
  5. Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol 2020; 11:2040620720910023.
  6. Jankovic M, Haupt R, Spinetta JJ, et al. Long-term survivors of childhood cancer: cure and care-the Erice Statement (2006) revised after 10 years (2016). J Cancer Surviv 2018; 12:647-50.
  7. Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol 2019; 37:2246-56.
Feedback Close

Please provide feedback for this touchEXPERT BRIEFING on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72